Claims for Patent: 7,563,810

Summary for Patent: 7,563,810

Title:	Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
Abstract:	Methods of treating, preventing and/or managing a myeloproliferative disease are disclosed. Specific methods encompass the administration of an immunomodulatory compound, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent, and/or the transplantation of blood or cells. Particular second active agents are capable of suppressing the overproduction of hematopoietic stem cells or ameliorating one or more of the symptoms of a myeloproliferative disease. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed.
Inventor(s):	Zeldis; Jerome B. (Princeton, NJ)
Assignee:	Celgene Corporation (Summit, NJ)
Application Number:	10/411,656
Patent Claims:	1. A method of treating a myeloproliferative disease, which comprises administering to a patient having a myeloproliferative disease a therapeutically effective amount of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione, or a pharmaceutically acceptable salt thereof, wherein the myeloproliferative disease is selected from the group consisting of polycythemia rubra vera, primary thrombocythemia, and agnogenic myeloid metaplasia, and wherein the therapeutically effective amount is from about 1 mg to about 50 mg per day. 2. A method of treating a myeloproliferative disease, which comprises administering to a patient having a myeloproliferative disease from about 5 mg to about 50 mg per day of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of at least one second active agent, wherein the myeloproliferative disease is selected from the group consisting of polycythemia rubra vera, primary thrombocythemia, and agnogenic myeloid metaplasia. 3. The method of claim 1 or 2, wherein the patient is refractory to a myeloproliferative disease treatment comprising thalidomide. 4. The method of claim 2, wherein the second active agent is a corticosteroid, platelet inhibitor, anticoagulant, thrombolytic agent, antifibrosis agent, all-trans retinoic acid, topoisomerase inhibitor, farnesyl transferase inhibitor, myelosuppressive agent or anti-cancer agent. 5. The method of claim 4, wherein the second active agent is interferon-.alpha., hydroxyurea, anagrelide, busulfan, arsenic trioxide, imatinib mesylate, exatecan mesylate, tipifarnib, vincristine, daunorubicin, prednisone, or a combination thereof. 6. The method of claim 1 or 2, wherein the myeloproliferative disease is primary or secondary. 7. A method of treating a myeloproliferative disease, which comprises administering to a patient having a myeloproliferative disease a therapeutically effective amount of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione, or a pharmaceutically acceptable salt thereof, before, during or after transplanting umbilical cord blood, placental blood, peripheral blood stem cell, hematopoietic stem cell preparation or bone marrow into the patient wherein the myeloproliferative disease is selected from the group consisting of polycythemia rubra vera, primary thrombocythemia, and agnogenic myeloid metaplasia, and wherein the therapeutically effective amount is from about 5 mg to about 50 mg per day. 8. The method of claim 1, 2, or 7, wherein the 3-(4-amino-1-oxo-1,3- dihydro-isoindol-2-yl)-piperidine-2,6-dione is administered orally. 9. The method of claim 8, wherein the 3-(4-amino-1-oxo-1,3- dihydro-isoindol-2-yl)-piperidine-2,6-dione is administered in the form of a capsule or tablet. 10. The method of claim 1, 2, or 7, wherein the 3-(4-amino-1-oxo-1,3- dihydro-isoindol-2-yl)-piperidine-2,6-dione is administered in an amount of about 5 mg, 10 mg, 25 mg or 50 mg per day. 11. The method of claim 1, 2, or 7, wherein the 3-(4-amino-1-oxo-1,3- dihydro-isoindol-2-yl)-piperidine-2,6-dione is administered in an amount of from about 5 mg to about 25 mg per day. 12. The method of claim 1, 2, or 7, wherein the 3-(4-amino-1-oxo-1,3- dihydro-isoindol-2-yl)-piperidine-2,6-dione is administered in an amount of about 25 mg per day. 13. The method of claim 1, 2, or 7, wherein the 3-(4-amino-1-oxo-1,3- dihydro-isoindol-2-yl)-piperidine-2,6-dione is a pharmaceutically acceptable salt. 14. A method of treating agnogenic myeloid metaplasia, which comprises administering to a patient having agnogenic myeloid metaplasia from about 5 mg to about 50 mg per day of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and a therapeutically effective amount of rituximab. 15. A method of treating agnogenic myeloid metaplasia, which comprises administering to a patient having agnogenic myeloid metaplasia from about 5 mg to about 50 mg per day of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and a therapeutically effective amount of fludarabine. 16. The method of claim 1, 2, or 7, wherein the compound is 3-(4-amino-1-oxo-1,3- dihydro-isoindol-2-yl)-piperidine-2,6-dione, having the formula: ##STR00009## as a free base.

Details for Patent 7,563,810

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2022-11-06
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2022-11-06
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2022-11-06